My ePortfolio Register   

Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.09.14
Views: 4893
Rating:

Dr David Currow - Flinders University, Adelaide, Australia

Prof David Currow of Flinders University Adelaide, Australia discusses research from a phase III trial at ESMO 2014 surrounding a new drug called Anamorelin for patients with advanced lung cancer. The new drug has been seen to improve appetite and body mass by mimicking the effects of the so-called “hunger hormone” ghrelin, which is secreted by the stomach.

Read the news story and watch the press conference for more.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence